Novartis Spinoff Fights Bid To Invalidate Eye Drug Patent

Law360, London (September 16, 2020, 6:56 PM BST) -- A Novartis AG eye care spinoff is defending the validity of its glaucoma treatment patent in consolidated litigation brought against generic-drug makers it has accused of infringing the protection for its eye drops.

Alcon Research LLC, a subsidiary of Novartis spinoff Alcon, denied in newly public court documents that the patent for its travoprost medication and an extension were invalid.

Alcon originally sued Aspire Pharma Ltd. and manufacturer Pharmathen SA in 2014, but the litigation was stayed until this year. The suit is now being heard alongside its later suit against British generics company Actavis UK Ltd., now rebranded as Accord...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!